Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study

Abstract Background Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approve...

Cijeli opis

Bibliografski detalji

Glavni autori:	Le-Qing Cao, Wen-Xuan Huo, Er-Lie Jiang, Yue-Wen Fu, Xiao-Jun Xu, Ping-Chong Lei, Ming-Feng Zhao, Zhi Chen, Shu-Xia Guo, Xiao-Bing Huang, Yan-Ming Zhang, Xian-Jing Wang, Guan-Chen Bai, Feng-Bo Jin, Qing-Sheng Li, Ming-Yang Deng, Hao Zhang, Xin-Feng Wang, Xiao-Jun Huang, Xiao-Dong Mo
Format:	Artigo
Jezik:	Inglês
Izdano:	KeAi Communications Co., Ltd. 2025-09-01
Serija:	Military Medical Research
Teme:	Xenopax Acute graft-versus-host disease (aGVHD) Steroid refractory (SR) Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Online pristup:	https://doi.org/10.1186/s40779-025-00640-0
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!